DIAZEPAM
Marketedupdated 2mo agoby Mylan Institutional Inc
Approvedcommunity read0 votes
indications
investigational
Epilepsy
all catalysts(1)
News(0)
no news has mentioned this drug yet
no news has mentioned this drug yet
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
comments(0)
5-min edit window · permanent after that